Aravive: Rises after dosing first patient in early-stage kidney cancer study

Aravive

08/03/2021 14:21

** Shares of clinical-stage biotechnology co  ARAV.O  up
10.2% to $7.12 premarket
    ** Co dosed its first patient in a phase 1b/2 clinical trial
to evaluate the safety and efficacy of AVB-500 in combination
with cabozantinib in patients who have progressed after
front-line treatment of advanced clear cell renal cell carcinoma
(ccRCC), a type of kidney cancer  urn:newsml:reuters.com:*:nGNX4gswpZ
    ** AVB-500 is an ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor
cell growth and is currently being evaluated in clinical trials
for the treatment of ovarian, kidney and urothelial cancer
    ** Trial to enroll up to 18 patients in three dosing arms
(15 mg/kg, 20 mg/kg and 25 mg/kg); Phase 2 portion of the same
trial will enroll up to 45 patients and investigate the
recommended AVB-500 dose identified versus cabozantinib alone
    ** BTIG initiates coverage with "buy" rating and PT of $26
    ** Stock up 14.5% YTD 

 (Reporting by Devik Jain in Bengaluru)
 ((Devik.Jain@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2062; ;))